The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Open accessAbstract
BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma. METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma. Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression-free survival, overall survival, and safety. RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval [CI], 15.8 to not reached), the estimated median progression-free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months. CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Self-citationOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,456
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citationFisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegović, B., Robertson, M. J., de Vos, S., Epner, E. M., Krishnan, A. Y., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Self-citationHeß, G., Herbrecht, R., Romaguera, J. E., Verhoef, G. E. G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F. C., Strahs, A. L., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
Self-citationde Rooij, M. F. M., Kuil, A., Geest, C. R., Eldering, E., Chang, B. Y., Buggy, J. J., Pals, S. T., & Spaargaren, M. (2012) · Blood · doi:10.1182/blood-2011-11-390989 · Cited by 558
Self-citationVelasquez, W. S., McLaughlin, P. J., Tucker, S., Hagemeister, F. B., Swan, F., Rodriguez, M. A., Romaguera, J. E., Rubenstein, E., & Cabanillas, F. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1169 · Cited by 426
Self-citationGoy, A. H., Sinha, R., Williams, M. E., Beşışık, S. K., Drach, J. W., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 358
Self-citationRomaguera, J. E., Fayad, L., Feng, L., Hartig, K., Weaver, P., Rodriguez, M. A., Hagemeister, F. B., Pro, B., McLaughlin, P. J., Younes, A., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08228.x · Cited by 243
Self-citationBruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Buggy, J. J., & Elias, L. (2012) · International Reviews of Immunology · doi:10.3109/08830185.2012.664797 · Cited by 213
Self-citationChang, B. Y., Francesco, M. R., de Rooij, M. F. M., Magadala, P., Steggerda, S. M., Huang, M. M., Kuil, A., Herman, S. E. M., Chang, S., Pals, S. T., et al. (2013) · Blood · doi:10.1182/blood-2013-02-482125 · Cited by 203
Self-citationRinaldi, A., Kwee, I., Taborelli, M., Largo, C., Uccella, S., Martin, V., Poretti, G., Gaïdano, G., Calabrese, G., Martinelli, G., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05883.x · Cited by 199
Hadzidimitriou, A., Agathangelidis, A., Darzentas, N., Murray, F., Delfau‐Larue, M., Pedersen, L. B., López, A. N., Dagklis, A., Rombout, P. D. M., Beldjord, K., et al. (2011) · Blood · doi:10.1182/blood-2011-03-343434 · Cited by 180
Self-citationWiestner, A. U. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4281 · Cited by 125
Anticoagulation therapy a risk factor for the development of chronic subdural hematoma
Aspegren, O. P., Åstrand, R., Lundgren, M. I., & Romner, B. (2012) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2012.10.008 · Cited by 113
Role of Bruton′s Tyrosine Kinase in B Cell Development
Maas, A., & Hendriks, R. W. (2001) · Journal of Immunology Research · doi:10.1155/2001/28962 · Cited by 106
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Rodríguez, M., Cabanillas, F., Velasquez, W. S., Hagemeister, F. B., McLaughlin, P. J., Swan, F., & Romaguera, J. E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1734 · Cited by 105
Self-citationRushworth, S. A., Bowles, K. M., Barrera, L. N., Murray, M. Y., Zaitseva, L., & MacEwan, D. J. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.09.008 · Cited by 105
LaCasce, A. S., Vandergrift, J. L., Rodriguez, M. A., Abel, G. A., Crosby, A. L., Czuczman, M. S., Nademanee, A. P., Blayney, D. W., Gordon, L. I., Millenson, M. M., et al. (2012) · Blood · doi:10.1182/blood-2011-07-369629 · Cited by 97
Chang, E. T., Canchola, A. J., Cockburn, M., Lu, Y., WANG, S. S., Bernstein, L., Clarke, C. A., & Horn‐Ross, P. L. (2011) · Blood · doi:10.1182/blood-2011-02-336065 · Cited by 71
Abbott boosts investment in NRF2 activators for reducing oxidative stress
Crunkhorn, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3655 · Cited by 71
How to manage mantle cell lymphoma
Dreyling, M. H., Ferrero, S., & Hermine, O. (2014) · Leukemia · doi:10.1038/leu.2014.171 · Cited by 46
Self-citationNovel targeted therapies for mantle cell lymphoma
Alinari, L., Christian, B. A., & Baiocchi, R. A. (2012) · Oncotarget · doi:10.18632/oncotarget.426 · Cited by 37
Wang, M. L., Fayad, L., Cabanillas, F., Hagemeister, F. B., McLaughlin, P. J., Rodriguez, M. A., Kwak, L. W., Zhou, Y., Kantarjian, H. M., & Romaguera, J. E. (2008) · Cancer · doi:10.1002/cncr.23880 · Cited by 33
Self-citationVose, J. M., & Šneller, V. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg704 · Cited by 32
Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?
Barışta, İ., Cabanillas, F., Romaguera, J. E., Khouri, I. F., Yang, Y., Smith, T. L., Strom, S. S., Medeiros, L. J., & Hagemeister, F. B. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf042 · Cited by 29
Self-citationBTK inhibitor shows positive results in B cell malignancies
Harrison, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3656 · Cited by 28
A Severe Combined Immunodeficient–hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma
Wang, M. L., Zhang, L., Han, X., Yang, J., Qian, J., Hong, S., Lin, P., Shi, Y., Romaguera, J. E., Kwak, L. W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4409 · Cited by 26
Self-citationThe Future of B-Cell Lymphoma Therapy: The B-Cell Receptor and its Downstream Pathways
Kenkre, V. P., & Kahl, B. S. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0127-0 · Cited by 21
Self-citationChang, B. Y., Francesco, M. R., Magadala, P., Huang, M. M., Spaargaren, M., Buggy, J. J., & Elias, L. (2011) · Blood · doi:10.1182/blood.v118.21.954.954 · Cited by 6
Self-citationChang, B. Y., Francesco, M. R., Steggerda, S. M., Chang, S., Magadala, P., Jawed, L., Thiemann, P. A., & Buggy, J. J. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-923 · Cited by 4
Self-citation
Research works printed but not linked: 1
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862
Self-citationSmall molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,813
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,205
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G. W., Lih, C., Williams, P. M., Shaffer, A. L., Gerecitano, J. F., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,155
Self-citation
Metadata
- Authors
- Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J. J., Chang, B. Y., Beaupre, D. M., Kunkel, L. A., & Blum, K. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Derriford Hospital (GB)
- Weill Cornell Medicine (US)
- Hackensack University Medical Center (US)
- University of Wisconsin–Madison (US)
- Jagiellonian University (PL)
- Stanford Medicine (US)
- University of Virginia (US)
- Northwell Health (US)
- Centrum Onkologii (PL)
- University of Manchester (GB)
- University Hospital Ulm (DE)
- LMU Klinikum (DE)
- Cancer Research UK (GB)
- Oregon Health & Science University (US)
- Pharmacyclics (United States) (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- ORCID
- Wang, Michael L.
- Rule, Simon
- Martin, Peter
- Goy, Andre
- Auer, Rebecca
- Kahl, Brad S.
- Jurczak, Wojciech
- Advani, Ranjana H.
- Romaguera, Jorge E.
- Williams, Michael E.
- Barrientos, Jacqueline C.
- Radford, John
- Stilgenbauer, Stephan
- Dreyling, Martin
- Johnson, Peter
- Spurgeon, Stephen E.
- Li, Lei
- Zhang, Liang
- Newberry, Kate
- Fang, Bingliang
- Chang, Betty Y.
- Blum, Kristie A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-08
- Volume
- 369
- Issue
- 6
- Pages
- 507-516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4513941
- OpenAlex
- W2154066874
- Cited by
- 1,685
- References
- 39
- Citations by year
- 2026: 59 · 2025: 67 · 2024: 91 · 2023: 115 · 2022: 142 · 2021: 127 · 2020: 138 · 2019: 127 · 2018: 141 · 2017: 161 · 2016: 133 · 2015: 189 · 2014: 147 · 2013: 42
- FWCI
- 127.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Society of Hematology
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Celgene
- Massachusetts Medical Society
- Les Laboratories Pierre Fabre
- Genentech
- Pharmacyclics
- National Cancer Institute (P30CA014520)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- ibrutinib, BTK inhibitors, mantle cell lymphoma, relapsed/refractory lymphoma, bortezomib, B cell receptor signaling, oral BTK inhibitor, overall response rate, progression-free survival, overall survival, adverse events, neutropenia
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Analysis, Lymphocyte Count, Drug Resistance, Neoplasm, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
